TOBIRA THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 19
- Market Cap
- -
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNon-alcoholic Fatty Liver DiseaseLiver Cirrhosis
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT03059446
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast - Dothan, Dothan, Alabama, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 1778
- Registration Number
- NCT03028740
- Locations
- 🇺🇸
Summit Internal Medicine, Birmingham, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02684799
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02685462
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02653625
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸Sutter Health, California Pacific Medical Center, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- Next